Trial Profile
A study evaluating correlation between pharmacokinetics and toxicity of deferasirox in patients with beta thalassaemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Pharmacokinetics
- 31 May 2017 New trial record